Biofrontera Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -98.7% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $0.57 | $1.09 | $2.77 | $18.34 | $150.40 | |
| P/S | 0.4x | 0.2x | 0.3x | 0.4x | 0.9x | 5.3x |
| P/B | 2.2x | 0.6x | 2.2x | 2.9x | 1.0x | 11.3x |
| EPS | -$1.04 | -$3.22 | -$13.02 | -$0.61 | -$85.60 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ENLVEnlivex Ltd. | $1.35 | 0.0x | 0.0x | — | 126.17% | $23.61M |
| NXTCNextCure, Inc. | $5.18 | — | 1.7x | — | -204.56% | $23.71M |
| CLRBCellectar Biosciences, Inc. | $2.53 | — | 0.7x | — | -119.57% | $23.91M |
| JSPRJasper Therapeutics, Inc. | $0.70 |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Company description provided by Yahoo Finance.
| Profit margin | -47.58% | -25.26% | -47.58% | -59.09% | -2.23% | -156.49% |
| ROE | -332.62% | -100.53% | -400.61% | -420.01% | -2.68% | -332.62% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 14.0x |
| — |
| -255.04% |
| $23.28M |
| CNSYCerenome Inc | $3.05 | 1.1x | 4.1x | — | -614.05% | $23.15M |
| AYTUAYTU Biopharma Inc | $2.25 | — | 0.7x | — | -97.42% | $24.15M |